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Abstract
Background: Randomised controlled trials (RCTs) are used to evaluate social and psychological interventions and
inform policy decisions about them. Accurate, complete, and transparent reports of social and psychological
intervention RCTs are essential for understanding their design, conduct, results, and the implications of the findings.
However, the reporting of RCTs of social and psychological interventions remains suboptimal. The CONSORT
Statement has improved the reporting of RCTs in biomedicine. A similar high-quality guideline is needed for the
behavioural and social sciences. Our objective was to develop an official extension of the Consolidated Standards of
Reporting Trials 2010 Statement (CONSORT 2010) for reporting RCTs of social and psychological interventions:
CONSORT-SPI 2018.
Methods: We followed best practices in developing the reporting guideline extension. First, we conducted a
systematic review of existing reporting guidelines. We then conducted an online Delphi process including 384
international participants. In March 2014, we held a 3-day consensus meeting of 31 experts to determine the
content of a checklist specifically targeting social and psychological intervention RCTs. Experts discussed previous
research and methodological issues of particular relevance to social and psychological intervention RCTs. They then
voted on proposed modifications or extensions of items from CONSORT 2010.
Results: The CONSORT-SPI 2018 checklist extends 9 of the 25 items from CONSORT 2010: background and objectives,
trial design, participants, interventions, statistical methods, participant flow, baseline data, outcomes and estimation,
and funding. In addition, participants added a new item related to stakeholder involvement, and they modified aspects
of the flow diagram related to participant recruitment and retention.
Conclusions: Authors should use CONSORT-SPI 2018 to improve reporting of their social and psychological intervention
RCTs. Journals should revise editorial policies and procedures to require use of reporting guidelines by authors and peer
reviewers to produce manuscripts that allow readers to appraise study quality, evaluate the applicability of findings to
their contexts, and replicate effective interventions.
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Background
When feasible and appropriate, randomised controlled
trials (RCTs) are used to evaluate social and psycho-
logical interventions, and to inform policy and practice
decisions [1–5]. To use reports of RCTs, readers need
information about their design, context, conduct, ana-
lysis, results, and interpretation. Like other types of
research, RCTs can provide biased estimates of inter-
vention effects if they are not conducted well, and syn-
theses of these RCTs may be biased if the trials are not
reported completely [6, 7]. Consequently, accurate,
complete, and transparent reports of RCTs are essential
for maximising their value [8], allowing replication
studies to build the evidence base [9], and facilitating
the comparison and implementation of effective inter-
ventions in real-world contexts [10].
Recent reviews have shown that reports of RCTs of
social and psychological interventions are often insuffi-
ciently accurate, comprehensive, and transparent to rep-
licate trials, assess their quality, and understand for
whom and under what circumstances an intervention
should be delivered [11–13]. For instance, authors often
do not report data on intervention implementation
[14], such as the specific techniques employed by inter-
vention providers; adaptation or tailoring of the inter-
vention to specific groups or individuals; materials used
to support intervention implementation; and partici-
pant behaviours [15]. Inadequate reporting can make it
difficult for researchers to replicate trials, for interven-
tion developers to design effective interventions, and
for providers to use the interventions in practice
[16]. A lack of sharing trial protocols, outcome data,
and materials required to implement social and psycho-
logical interventions has been identified as a major rea-
son for limitations in the ability of behavioural and
social scientists to reproduce trial procedures, replicate
trial results, and effectively synthesise evidence on these
interventions [16–21]. The review of trials that we con-
ducted in the first phase of this project (n = 239) re-
vealed that many CONSORT items were poorly
reported in the behavioural and social science litera-
ture. Such items included identification as a rando-
mised trial in titles; information about masking,
methods for sequence generation, and allocation con-
cealment; and details about the actual delivery of the
interventions. Only 11 of 40 journals we examined ref-
erenced reporting guidelines in ‘Instructions to
Authors’ [11]. This inefficient use of resources for re-
search likely contributes to the suboptimal dissemin-
ation of potentially effective interventions [8, 22],
overestimations of intervention efficacy [23], and re-
search waste of investment to the order of hundreds of
billions of dollars [22]. As in other areas of research,
transparent and detailed reporting of social and
psychological intervention RCTs is needed to minimise
reporting biases and maximise the credibility and utility
of this research evidence [24, 25].
The CONSORT Statement
To address the problems in scientific manuscripts out-
lined above, reporting guidelines have been developed
that include minimum standards for describing specific
types of research [26]. Reporting guidelines do not pro-
vide recommendations for study design or conduct.
Instead, they focus on reporting what was done
(methods) and what was found (results). In 1996, a
group of scientists and journal editors published the
CONSORT (Consolidated Standards of Reporting
Trials) Statement to help authors report RCTs in bio-
medicine completely and transparently [27]. In light of
feedback and emerging evidence, the CONSORT Group
updated this reporting guideline in 2001 [28] and again
in 2010 [29]. CONSORT 2010 includes a 25-item
checklist and flow diagram. An extensive Explanation
and Elaboration (E&E) document serves as a user man-
ual that explains the rationale behind each checklist
item, provides the methodological rationale for each
checklist item, and gives examples of trial details
adequately reported in accordance with each checklist
item [26].
The CONSORT Statement has had an important im-
pact in medicine. An early evaluation showed that
reporting in the BMJ, Lancet, and JAMA improved after
the publication of the first CONSORT Statement [30].
Systematic reviews comparing articles in medical jour-
nals endorsing CONSORT compared with journals not
endorsing it found that the former are significantly
more likely to describe the method of sequence gener-
ation, allocation concealment, and participant flow [31].
These effects remain even after controlling for the im-
pact factor of the journals and study outcomes [32].
Over 600 journals and prominent editorial groups (in-
cluding the International Committee of Medical Journal
Editors, the Council of Science Editors, and the World
Association of Medical Editors) officially endorse the
CONSORT Statement.
Scope of CONSORT-SPI 2018
The CONSORT 2010 Statement focuses on individually
randomised two-group parallel trials [29]. To address
the varying amount of additional information needed
for different types of trial, the CONSORT Group has
created extensions (http://www.consort-statement.org/
extensions). These extensions target different types of
trial designs, such as cluster randomised [33], noninfe-
riority [34], pragmatic [35], N-of-1 [36], and feasibility
[37]; different types of trial data, such as patient-re-
ported outcomes [38], abstracts [39], and harms [40];
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and different types of intervention (see next section)
[41–43]. Intervention extensions of CONSORT are orga-
nised by techniques, such as non-pharmacologic [41],
herbal medicinal products [42], and acupuncture [43].
Social and psychological interventions go beyond
simply adding techniques or using different techniques
compared to biomedical interventions; they often use
concepts, theories, and taxonomies that are distinct
from those used by the biomedical scientists targeted
by the CONSORT extension for non-pharmacologic
treatments [21, 44–48]. To delineate the scope of
CONSORT for social and psychological interventions
(CONSORT-SPI), we define interventions by their
mechanisms of action: i.e., how these interventions
function to affect desired outcomes [49, 50]. That is,
social and psychological interventions are actions
intended to modify processes and systems that are so-
cial and psychological in nature (such as cognitions,
emotions, behaviours, norms, relationships, and salient
aspects of the environment) and are hypothesised to be
influences on outcomes of interest [51, 52].
Social and psychological interventions can be
complex in several ways [12, 50]. For example, these in-
terventions cover an assortment of coordinated ac-
tions—such as practices, programmes, and policies—
that often involve multiple interacting components.
The units targeted by these interventions may include
individuals, groups, or even places, and outcomes may
be measured at any of these levels. The behaviours of
both providers and recipients must be understood if
the intervention and its effects are to be understood
[53–55]. Social and psychological interventions may
not follow strictly standardised implementation proce-
dures [56], and effects may depend on aspects of the
hard-to-control dynamic systems in which they occur
[57–59]. For these reasons, readers of social and psy-
chological intervention research are interested in more
than just effect estimates—they require information
about how and why these interventions work, for
whom, and under what conditions [60].
Methods
We developed an official CONSORT Extension that ad-
dresses the minimum criteria that need to be met when
reporting RCTs evaluating the effects of social and psy-
chological interventions (CONSORT-SPI 2018). We
followed recommended practices for developing and
disseminating reporting guidelines [26] as described in
the study protocol [61]. The methods and results of the
systematic review, Delphi process, and consensus meet-
ing followed a pre-specified protocol reported in full
elsewhere [11, 61]. We briefly summarise the process
below (Fig. 1).
Systematic reviews
We first conducted a systematic review to assess the ad-
herence of RCTs evaluating social and psychological in-
terventions to existing reporting standards, and to
identify potential items for the CONSORT-SPI 2018
checklist and flow diagram [11].
Online Delphi process
We then conducted an international online Delphi
process between September 2013 and February 2014 to
prioritise the list of potential items for the
CONSORT-SPI 2018 checklist and flow diagram that
were identified in the systematic review. To encourage
Fig. 1 Flow of potential checklist items through CONSORT-SPI 2018
project
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Table 1 The CONSORT-SPI 2018 checklist
Section Item # CONSORT 2010 CONSORT-SPI 2018
Title and abstract
1a Identification as a randomised trial in the title§
1b Structured summary of trial design, methods, results,
and conclusions (for specific guidance see CONSORT
for Abstracts)§
Refer to CONSORT extension for social and psychological
intervention trial abstracts
Introduction
Background
and objectives
2a Scientific background and explanation of rationale§
2b Specific objectives or hypotheses§ If pre-specified, how the intervention was hypothesised
to work
Methods
Trial design 3a Description of trial design (such as parallel, factorial),
including allocation ratio§
If the unit of random assignment is not the individual,
please refer to CONSORT for Cluster Randomised Trials [33]
3b Important changes to methods after trial
commencement (such as eligibility criteria),
with reasons
Participants 4a Eligibility criteria for participants§ When applicable, eligibility criteria for settings and those
delivering the interventions
4b Settings and locations where the data were collected
Interventions 5 The interventions for each group with sufficient details
to allow replication, including how and when they
were actually administered§
5a Extent to which interventions were actually delivered
by providers and taken up by participants as planned
5b Where other informational materials about delivering
the intervention can be accessed
5c When applicable, how intervention providers were assigned
to each group
Outcomes 6a Completely defined pre-specified outcomes, including
how and when they were assessed§
6b Any changes to trial outcomes after the trial
commenced, with reasons
Sample size 7a How sample size was determined§
7b When applicable, explanation of any interim analyses
and stopping guidelines
Randomisation
Sequence
generation
8a Method used to generate the random allocation
sequence
8b Type of randomisation; details of any restriction
(such as blocking and block size)§
Allocation
concealment
mechanism
9 Mechanism used to implement the random allocation
sequence, describing any steps taken to conceal the
sequence until interventions were assigned§
Implementation 10 Who generated the random allocation sequence, who
enrolled participants, and who assigned participants to
interventions§
Awareness of
assignment
11a Who was aware of intervention assignment after
allocation (for example, participants, providers, those
assessing outcomes), and how any masking was done
11b If relevant, description of the similarity of interventions
Analytical
methods
12a Statistical methods used to compare group outcomes§ How missing data were handled, with details of any
imputation method
12b Methods for additional analyses, such as subgroup
analyses, adjusted analyses, and process evaluations
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widespread participation, we published commentaries in
several journals publishing trial reports in the fields of
addiction, criminology, education, adult and child psych-
ology and psychiatry, public health, and social work [11,
62–68], directing readers to a recruitment website where
they could register. We also invited members of profes-
sional bodies, funders, policymakers, journal editors,
practitioners, user representatives, and other stake-
holders to participate. We encouraged all identified
stakeholders to invite any further colleagues to partici-
pate. We sent these participants a two-round survey to
rate the importance of including proposed items in the
CONSORT-SPI 2018 checklist and to provide qualita-
tive feedback (survey items can be accessed at the
Table 1 The CONSORT-SPI 2018 checklist (Continued)
Section Item # CONSORT 2010 CONSORT-SPI 2018
Results
Participant flow
(a diagram
is strongly
recommended)
13a For each group, the numbers randomly assigned,
receiving the intended intervention, and analysed
for the outcomes§
Where possible, the number approached, screened, and
eligible prior to random assignment, with reasons for
non-enrolment
13b For each group, losses and exclusions after
randomisation, together with reasons§
Recruitment 14a Dates defining the periods of recruitment and follow-up
14b Why the trial ended or was stopped
Baseline data 15 A table showing baseline characteristics for each group§ Include socioeconomic variables where applicable
Numbers analysed 16 For each group, number included in each analysis
and whether the analysis was by original assigned
groups§
Outcomes
and estimation
17a For each outcome, results for each group, and the
estimated effect size and its precision (such as 95%
confidence interval)§
Indicate availability of trial data
17b For binary outcomes, the presentation of both absolute
and relative effect sizes is recommended
Ancillary analyses 18 Results of any other analyses performed, including
subgroup analyses, adjusted analyses, and process
evaluations, distinguishing pre-specified from
exploratory
Harms 19 All important harms or unintended effects in each
group (for specific guidance see CONSORT for Harms)
Discussion
Limitations 20 Trial limitations, addressing sources of potential bias,
imprecision, and, if relevant, multiplicity of analyses
Generalisability 21 Generalisability (external validity, applicability) of the
trial findings§
Interpretation 22 Interpretation consistent with results, balancing benefits
and harms, and considering other relevant evidence
Important information
Registration 23 Registration number and name of trial registry
Protocol 24 Where the full trial protocol can be accessed, if available
Declaration
of interests
25 Sources of funding and other support; role of funders Declaration of any other potential interests
Stakeholder
involvement*
26a Any involvement of the intervention developer in the
design, conduct, analysis, or reporting of the trial
26b Other stakeholder involvement in trial design, conduct,
or analyses
26c Incentives offered as part of the trial
This table lists items from the CONSORT 2010 checklist (with some modifications for social and psychological intervention trials as described in Table 2) and additional
items in the CONSORT-SPI 2018 extension. Empty rows in the ‘CONSORT-SPI 2018’ column indicate that there is no extension to the CONSORT 2010 item
*We strongly recommended that the CONSORT-SPI 2018 Explanation and Elaboration (E&E) document be reviewed when using the CONSORT-SPI 2018 checklist
for important clarifications on each item
§An extension item for cluster trials exists for this CONSORT 2010 item
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project’s ReShare site: https://doi.org/10.5255/UKDA-SN-
851981). We synthesised the results of the first survey
and sent these to participants, who then completed
the second survey, which was designed to explore
areas of disagreement and to resolve questions arising
during the first round.
Consensus meeting
Following the Delphi process, we held a three-day
in-person consensus meeting to determine the con-
tent of the CONSORT-SPI 2018 checklist and flow
diagram, as well as the accompanying E&E document
(March 2014). We used established methods [69]
from previous CONSORT meetings [29, 35, 41, 70].
Participants included 31 experts from the Delphi
process (see Table 6 in the Appendix), whom we se-
lected purposively to include key stakeholders from
targeted disciplines (e.g. public health, social work,
education, criminology, and clinical psychology) and
professional roles (e.g. trialists, funders, and journal
editors) [71].
Prior to the meeting, we sent participants background
literature [9, 11, 26, 39, 61, 64, 72], results from the
Delphi process, and the meeting agenda. On the first
day, participants discussed the background literature
and its applicability to the various disciplines and
professional roles represented at the meeting. During
the second day, participants discussed and voted on
potential checklist and flow diagram items nominated
during the Delphi process using anonymous electronic
ballots. On the third day, participants voted on the
remaining items and discussed strategies for dissemin-
ation. Participants were asked to consider the value of
each item based on the evidence presented and to
vote on whether each item was essential when report-
ing all social and psychological intervention RCTs.
When voting, participants could select ‘exclude’, ‘in-
clude’, or ‘unsure’.
In the first round of voting, only items endorsed as
‘include’ by ≥70% of participants were included in the
checklist [73, 74]. We excluded all other items unless
at least two participants proposed they be reconsid-
ered. In this second round of voting, items endorsed
as ‘include’ by ≥80% of participants were also incor-
porated in the CONSORT-SPI 2018 checklist. Partici-
pants suggested that several ‘excluded’ items should
be discussed in the E&E document.
Post-meeting activities
After the consensus meeting, we finalised the
CONSORT-SPI 2018 checklist and flow diagram. We
then drafted the Extension Statement (this manu-
script), as well as an E&E document that serves as a
user manual for the checklist. We distributed these
documents to consensus meeting participants for
feedback and revision, and we incorporated their
comments in the final version of this manuscript and
the accompanying E&E. We also discussed how best
to optimise our strategy for disseminating and imple-
menting these documents.
Results
Systematic review
The systematic review of reporting guidance identified
14 relevant reporting guidelines and 5 reporting
Table 2 Noteworthy changes to CONSORT 2010 items in the
CONSORT-SPI 2018 checklist
• Item 6a. The distinction between ‘primary’ versus ‘secondary’ outcomes
has been removed.
• Item 11. ‘Blinding’ has been changed to ‘Awareness of assignment’
and ‘masking’ in the section heading and item wording, respectively.
These changes address concerns about the use of the term ‘blinding’
as well as the need to emphasise the issue of awareness of
assignment by providers and participants in social and psychological
intervention trials.
• Item 12. The section heading ‘Statistical methods’ has been
changed to ‘Analytical methods’ because some methods may be
qualitative in social and psychological intervention RCTs.
• Item 12a. The distinction between ‘primary’ versus ‘secondary’
outcomes has been removed.
• Item 12b. Process evaluations are specifically highlighted.
• Item 13a. The distinction between ‘primary’ versus ‘secondary’
outcomes has been removed.
• Items 13a and 16. The wording ‘number of participants’ has been
changed to ‘number’ because the term ‘participants’ is not
appropriate for RCTs in which the unit of intervention is a
geographic area. While social and psychological interventions may
target individual participants or groups of individuals, such as
families or schools, they may also involve place-based techniques
that target geographic units and examine area-level effects.
However, for convenience and consistency with the CONSORT
2010 guidance [72], the CONSORT-SPI 2018 checklist and E&E will
refer to the unit targeted by the intervention as ‘participants’,
though ‘participants’ throughout this guidance is meant to stand
for ‘participating units’ or the unit being targeted by the intervention
[87], which may include geographic units.
• Item 15. The words ‘clinical and demographic’ have been removed
because this checklist targets interventions that may not be medical
in nature or have health outcomes, and thus to emphasise the need
to report important baseline characteristics irrespective of their nature.
• Item 16. The parenthetical ‘(denominator)’ has been removed.
The term implied the use of dichotomous outcomes, whereas
continuous outcomes are extremely prevalent in social and
psychological intervention RCTs.
• Item 17a. The distinction between ‘primary’ versus ‘secondary’
outcomes has been removed.
• Items 23–25. The section ‘Other Information’ has been changed to
‘Important Information’ because consensus meeting participants
had concerns that ‘Other’ makes the requested information appear
to be of secondary importance to previous sections.
• Item 25. The phrase ‘such as supply of drugs’ has been removed
because drug trials are not in the purview of this extension by
definition.
• Item 26: New item. A new sub-section in ‘Important Information’
called ‘Stakeholder Involvement’ has been added because
consensus meeting participants thought such a sub-section would
best fit the three sub-items currently allocated to it.
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assessment tools. These tools included a total of 147
potential items to consider for the CONSORT-SPI
2018 checklist, 89 of which were not included in the
CONSORT checklist [11].
Online Delphi process
With input from the project’s International Advisory
Group, we included 77 potential checklist items from
the systematic review in the first round of the
modified Delphi process. We recruited 384 Delphi
participants from 32 countries working in over a
dozen areas of social and psychological intervention,
including academics, researchers, practitioners, journal
editors, research funders, policymakers, and recipients
of social and psychological interventions. The Delphi
process yielded 58 potential items as important to
consider for inclusion in the CONSORT-SPI 2018
checklist.
Consensus meeting
During the consensus meeting, participants voted to
extend 9 of the 25 items in the CONSORT 2010 check-
list: background and objectives, trial design, partici-
pants, interventions, statistical methods, participant
flow, baseline data, outcomes and estimation, and fund-
ing. These extended checklist items addressed the need
for reports of RCTs of social and psychological inter-
ventions to describe: the hypotheses for how the inter-
vention might work, the eligibility criteria for settings
and providers, the actual provider delivery and partici-
pant uptake of the interventions, the intervention mate-
rials, how missing data were handled, participant
recruitment, socioeconomic baseline variables, avail-
ability of trial data, author declarations of interest, in-
volvement of the intervention developer in the trial,
and details of any incentives offered (Table 1). Partici-
pants also voted to add a new item about stakeholder
involvement, and they recommended modifications to
Fig. 2 The CONSORT-SPI 2018 flow diagram
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existing CONSORT 2010 checklist items (Table 2). The
flow diagram (Fig. 2) to address the unique needs of so-
cial and psychological intervention trials was also
modified—specifically, the number of participants
approached during enrolment and the number of pro-
viders, organisations, and areas (as appropriate) allo-
cated to each trial arm. To further facilitate use of
CONSORT-SPI 2018, we have provided a tailored
CONSORT Extension for Abstracts (Table 3) [39] and a
CONSORT Extension for Cluster Randomised Trials
(Tables 4 and 5) [33] for social and psychological inter-
vention trials.
Discussion
The CONSORT-SPI 2018 Extension is designed to as-
sist authors in writing reports of social and psycho-
logical intervention RCTs and to assist peer reviewers
and editors in assessing these manuscripts. While we
recommend that authors report items in the checklist
in the relevant manuscript section (i.e., introduction,
methods, results, or discussion), the format of an article
will depend on journal style, editorial decisions, expec-
tations within a particular research area, and author
discretion. At a minimum, authors should address each
checklist item somewhere in the article with the appro-
priate level of detail and clarity. We recommend sub-
headings within major sections—particularly the
methods and results sections—to help ease of reading.
The accompanying CONSORT-SPI 2018 E&E docu-
ment is a user manual for the CONSORT-SPI 2018
checklist, providing a concise rationale for and descrip-
tion of how best to adhere to each checklist item. We
recommend that authors preparing reports of social
and psychological intervention RCTs consult the
CONSORT-SPI 2018 E&E document when using the
CONSORT-SPI 2018 checklist.
This guideline may prove useful to several different
stakeholders [75]. Researchers can use CONSORT-SPI
2018, along with the SPIRIT Statement, during trial de-
sign to ensure they consider the essential study aspects
Table 3 Items to report in journal or conference abstracts for social and psychological intervention trials [39]
Section CONSORT abstract item Relevant CONSORT-SPI item
Title Identification of the study as randomised
Authors Contact details for the corresponding author
Trial design Description of the trial design (e.g. parallel, cluster,
noninferiority)
If the unit of random assignment is not the individual,
refer to CONSORT for Cluster Randomised Trials and
report the items included in its extension for abstracts [33]
Methods
Participants Eligibility criteria for participants and the settings where
the data were collected
When applicable, the eligibility criteria for the setting of
the intervention delivery and the eligibility criteria for the
persons who delivered the interventions
Interventions Interventions intended for each group
Objective Specific objective or hypothesis If pre-specified, how the intervention was hypothesised
to work
Outcomes Clearly defined primary outcome for this report
Randomisation How participants were allocated to interventions
Awareness of assignment Who was aware of intervention assignment after
allocation (for example, participants, providers, those
assessing outcomes), and how any masking was done
Results
Number randomly assigned Number randomised to each group
Recruitment Trial status
Interventions Extent to which interventions were actually delivered
by providers and taken up by participants as planned
Number analysed Number analysed in each group
Outcomes For the primary outcome, a result for each group
and the estimated effect size and its precision
Harms Important adverse events or side effects
Conclusions General interpretation of the results
Trial registration Registration number and name of trial register
Funding Source of funding
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they will have to describe in future manuscripts. Use of
CONSORT-SPI 2018 throughout a trial (from design to
reporting) can help improve the accuracy, complete-
ness, and transparency of the final manuscript. Journal
editors can enforce policies and procedures to ensure
that CONSORT-SPI 2018 is actually used by authors,
editors and peer reviewers to improve the social and
psychological RCT manuscripts they publish [76]. Re-
search funders who adopt CONSORT-SPI 2018 and
other reporting guidelines may receive higher quality
grant applications, as well as facilitate the commission-
ing of the most important and rigorous studies while
helping to reduce research waste. Policymakers, practi-
tioners, and systematic reviewers who encourage re-
searchers to use CONSORT-SPI 2018 may find this
leads to higher quality publications, which these stake-
holders can then use to identify and implement effect-
ive interventions for populations and settings of
interest. In addition, faculty could use reporting guide-
lines to train the next generation of researchers, peer
reviewers, and journal editors [77].
In highlighting prospective trial registration [78], the
publication of protocols [79], and increased sharing of
trial data [16, 80], all of which are uncommon in social
and psychological intervention research, CONSORT-SPI
2018 also complements other efforts to improve re-
search transparency. Examples of such efforts include
the Template for Intervention Description and Replica-
tion (TIDieR) checklist (which will replace CONSORT
2010 Item 5) [9], the Behaviour Change Technique tax-
onomy [21, 44], the Berkeley Initiative for Transparency
in the Social Sciences [81], the Data Access and
Research Transparency Statement [82], the Center for
Open Science [19], the Transparency and Openness
Promotion guidelines [16], and the Human Behaviour-
Change Project [83].
Strengths and limitations
We followed recommended best practices in the devel-
opment of these reporting guidelines and advocate their
use to future reporting guideline developers [26]. A
challenge that we experienced, and which other report-
ing guideline developers have faced [84], was the large
number of potential checklist items that participants
considered to be important for a CONSORT-SPI 2018
Table 4 Items to report in the abstract for cluster randomised social and psychological intervention trials [33]
Section CONSORT Abstract item Relevant CONSORT Cluster extension item
Title Identification of the study as randomised Identification of study as cluster randomised
Authors Contact details for the corresponding author
Trial design Description of the trial design (e.g. parallel, cluster,
noninferiority)
Methods
Participants Eligibility criteria for participants and the settings
where the data were collected
Eligibility criteria for clusters
Interventions Interventions intended for each group
Objective Specific objective or hypothesis Whether objective or hypothesis pertains to the cluster
level, the individual participant level, or both
Outcomes Clearly defined primary outcome for this report Whether the primary outcome pertains to the cluster
level, the individual participant level, or both
Randomisation How participants were allocated to interventions How clusters were allocated to interventions
Awareness of assignment Who was aware of intervention assignment after
allocation (for example, participants, providers, those
assessing outcomes), and how any masking was done
Results
Number randomly assigned Number of participants randomised to each group Number of clusters randomised to each group
Recruitment Trial status
Number analysed Number of participants analysed in each group Number of clusters analysed in each group
Outcomes For the primary outcome, a result for each group and
the estimated effect size and its precision
Results at the cluster or individual level as applicable
for each primary outcome
Harms Important adverse events or side effects
Conclusions General interpretation of the results
Trial registration Registration number and name of trial register
Funding Source of funding
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guideline. As with the CONSORT 2010 Statement,
CONSORT-SPI 2018 represents a set of minimum
reporting criteria and does not preclude individual au-
thors from addressing other issues that they deem im-
portant to ensure complete and transparent reporting.
For example, for social and psychological interventions
utilising mobile phones, additional details may need to
be reported in trial manuscripts [85].
In addition, as in the development of previous
CONSORT guidelines, other items fundamental to an
RCT have not been included (such as approval by an insti-
tutional ethical review board) because journals and insti-
tutions address these issues in other ways [29]. We
encourage users of this guideline to provide feedback on
the appropriateness of the content in the CONSORT-SPI
2018 checklist and its accompanying E&E document.
Endorsement
As a recognised extension of the CONSORT 2010
Statement, journals and organisations already endorsing
the CONSORT guidelines can easily extend their sup-
port to CONSORT-SPI 2018. We encourage other
journals and organisations that publish social and
psychological intervention RCTs to endorse
CONSORT-SPI 2018 and to register their official
support on the CONSORT website (http://www.con
sort-statement.org/about-consort/endorsement). Journal
endorsement policies that include monitoring of adher-
ence to the checklist are essential for complete and
transparent reporting [31]. To maximise the potential
impact of CONSORT-SPI 2018, editors should consider
requiring authors to submit a completed CONSORT-
SPI 2018 checklist as a separate document when
Table 5 Items to report in the main text for cluster randomised social and psychological intervention trials [33]
Section Item # Cluster extension item
Title 1a Identification as a cluster randomised trial in the title
Abstract 1b See Table 4
Introduction
Background and
objectives
2a Rationale for using a cluster design
2b Whether objectives pertain to the cluster level, the individual participant level, or both
Methods
Trial design 3a Definition of cluster and description of how the design features apply to the clusters
Participants 4a Eligibility criteria for clusters
Interventions 5 Whether interventions pertain to the cluster level, the individual participant level, or both
Outcomes 6a Whether outcome measures pertain to the cluster level, the individual participant level, or both
Sample size 7a Method of calculation, number of clusters(s) (and whether equal or unequal cluster sizes are assumed), cluster
size, a coefficient of intracluster correlation (ICC or k), and an indication of its uncertainty
Randomisation
Sequence generation 8b Details of stratification or matching if used
Allocation concealment
mechanism
9 Specification that allocation was based on clusters rather than individuals and whether allocation concealment
(if any) was at the cluster level, the individual participant level, or both
Implementation 10a Who generated the random allocation sequence, who enrolled clusters, and who assigned clusters to
interventions
10b Mechanism by which individual participants were included in clusters for the purposes of the trial (such as
complete enumeration, random sampling)
10c From whom consent was sought (representatives of the cluster, individual cluster members, or both) and
whether consent was sought before or after randomisation
Analytical methods 12a How clustering was taken into account
Results
Participant flow (a diagram
is strongly recommended)
13a For each group, the numbers of clusters that were randomly assigned, received the intended treatment, and were
analysed for the primary outcome
13b For each group, losses and exclusions for both clusters and individual cluster members
Baseline data 15 Baseline characteristics for the individual and cluster levels as applicable for each group
Numbers analysed 16 For each group, the number of clusters included in each analysis
Outcomes and estimation 17a Results at the individual or cluster level as applicable and a coefficient of intracluster correlation (ICC or k) for
each primary outcome
Generalisability 21 Generalisability to clusters or individual participants (as relevant)
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reporting social and psychological intervention RCTs,
and we recommend that editors should check that all
items have been included before sending manuscripts
for peer review. Endorsing journals should consider
adding the following statement to their ‘Instructions to
Authors’ [36]:
JOURNAL NAME requires a completed CONSORT-
SPI 2018 checklist as a condition for submitting
manuscripts about randomised trials of social and
psychological interventions. We recommend that
your submission addresses each item in the
CONSORT-SPI 2018 checklist. Taking the time to
ensure your manuscript meets these basic reporting
requirements will greatly improve your manuscript,
and may potentially enhance its chances for even-
tual publication.
We also recommend that researchers, editors, peer
reviewers, funders, and educators consult the CON-
SORT website (http://www.consort-statement.org) for
other relevant CONSORT Extensions (e.g. the exten-
sion for cluster randomised trials) [33], as well as the
Enhancing the Quality and Transparency of Health
Research (EQUATOR) Network for up-to-date infor-
mation on other reporting guidelines (http://www.e
quator-network.org) that may be of relevance to their
study.
Conclusion
CONSORT-SPI 2018, like other CONSORT guidelines,
is an evolving tool that requires regular reappraisal
and modifications as new evidence emerges and as
scientific consensus changes. We invite interested
stakeholders to contact us with feedback or to con-
tribute to the guideline’s ongoing development, in-
cluding individuals or groups who wish to translate
the CONSORT-SPI 2018 checklist into other lan-
guages or those who wish to evaluate the impact of
the CONSORT-SPI 2018 checklist on future trial
reporting [31, 86]. To provide feedback and access
the most recent version of the CONSORT-SPI 2018
checklist and E&E document, visit the project
(https://www.birmingham.ac.uk/schools/social-policy/
departments/social-policy-sociology-criminology/research/
projects/2017/Consort-SPI.aspx) and CONSORT websites
(http://www.consort-statement.org).
Appendix
Table 6 lists the members of the CONSORT-SPI Group
who were participated to represent the stakeholder
groups in the consensus meeting.
Table 6 The CONSORT-SPI Group
Member Organisation
Project Executive
Sean Grant RAND Corporation
Sally Hopewell University of Oxford
Evan Mayo-Wilson Johns Hopkins University
Susan Michie University College London
David Moher Ottawa Health Research Institute
Paul Montgomery University of Birmingham
Geraldine Macdonald University of Bristol
International Advisory Board
Stakeholder Representatives of Behavioural and Social Science
Disciplines
J. Lawrence Aber New York University
David Clark University of Oxford
Manuel Eisner University of Cambridge
Frances Gardner University of Oxford
Steve Hollon Vanderbilt University
Lawrence Sherman University of Cambridge
James Thomas UCL Institute of Education
Elizabeth Waters
(deceased)
University of Melbourne
Joanne Yaffe University of Utah
Stakeholder Representatives of Intervention Research Methodologists
Andrew Booth University of Sheffield
Peter Craig University of Glasgow
Larry Hedges Northwestern University
Stakeholder Representatives of Journals
Doug Altman Trials
Mark W. Fraser Journal of the Society for Social Work and
Research
Spyros
Konstantopoulos
Journal of Research on Educational
Effectiveness
Kenneth McLeroy American Journal of Public Health
Arthur Nezu Journal of Consulting and Clinical
Psychology
Edmund Sonuga-Barke Journal of Child Psychology and Psychiatry
Gary VandenBos American Psychologist
Robert West Addiction
Stakeholder Representatives of Research Funders
Robert Kaplan Office of Behavioural and Social Sciences
Research
Peter Kaufmann National Heart, Lung, and Blood Institute
Brian Mittman Patient-Centered Outcomes Research
Institute
Montgomery et al. Trials  (2018) 19:407 Page 11 of 14
Acknowledgements
We thank all of the stakeholders who have provided their input to the project.
CONSORT-SPI Group: J. Lawrence Aber (Willner Family Professor of Psychology
and Public Policy and University Professor, Steinhardt School of Culture,
Education, and Human Development, New York University), Doug Altman
(Professor of Statistics in Medicine and Director of the UK EQUATOR Centre,
Centre for Statistics in Medicine, University of Oxford), Kamaldeep Bhui
(Professor of Cultural Psychiatry & Epidemiology, Wolfson Institute of Preventive
Medicine, Queen Mary University of London), Andrew Booth (Reader in
Evidence Based Information Practice and Director of Information, Information
Resources, University of Sheffield), David Clark (Professor and Chair of
Experimental Psychology, Experimental Psychology, University of Oxford), Peter
Craig (Senior Research Fellow, MRC/CSO Social and Public Health Sciences Unit,
Institute of Health & Wellbeing, University of Glasgow), Manuel Eisner (Wolfson
Professor of Criminology, Institute of Criminology, University of Cambridge),
Mark W. Fraser (John A. Tate Distinguished Professor for Children in Need,
School of Social Work, The University of North Carolina at Chapel Hill), Frances
Gardner (Professor of Child and Family Psychology, Department of Social Policy
and Intervention, University of Oxford), Sean Grant (Behavioural & Social
Scientist, Behavioural & Policy Sciences, RAND Corporation), Larry Hedges
(Board of Trustees Professor of Statistics and Education and Social Policy,
Institute for Policy Research, Northwestern University), Steve Hollon (Gertrude
Conaway Vanderbilt Professor of Psychology, Psychological Sciences, Vanderbilt
University), Sally Hopewell (Associate Professor, Oxford Clinical Trials Research
Unit, University of Oxford), Robert Kaplan (Professor Emeritus, Department of
Health Policy and Management, Fielding School of Public Health, University of
California, Los Angeles), Peter Kaufmann (Leader, Behavioural Medicine and
Prevention Research Group, National Heart, Lung, and Blood Institute, National
Institutes of Health), Spyros Konstantopoulos (Professor, Department of
Counselling, Educational Psychology, and Special Education, Michigan State
University), Geraldine Macdonald (Professor of Social Work, School for Policy
Studies, University of Bristol), Evan Mayo-Wilson (Assistant Scientist, Division of
Clinical Trials and Evidence Synthesis, Department of Epidemiology, Johns
Hopkins University), Kenneth McLeroy (Regents & Distinguished Professor,
Health Promotion and Community Health Sciences, Texas A&M University),
Susan Michie (Professor of Health Psychology and Director of the Centre for
Behaviour Change, University College London), Brian Mittman (Research
Scientist, Department of Research and Evaluation, Division of Health Services
Research and Implementation Science, Kaiser Permanente), David Moher
(Senior Scientist, Clinical Epidemiology Program, Ottawa Hospital Research
Institute), Paul Montgomery (Professor of Social Intervention, Department of
Social Work and Social Care, University of Birmingham), Arthur Nezu
(Distinguished University Professor of Psychology, Department of Psychology,
Drexel University), Lawrence Sherman (Director of the Jerry Lee Centre for
Experimental Criminology and Chair of the Cambridge Police Executive
Programme, the Institute of Criminology, University of Cambridge.), Edmund
Sonuga-Barke (Professor of Developmental Psychology, Psychiatry, and
Neuroscience, Institute of Psychiatry, King’s College London), James Thomas
(Professor Social Research and Policy, UCL Institute of Education, University
College London), Gary VandenBos (Executive Director, Office of Publications
and Databases, American Psychological Association), Elizabeth Waters
(Jack Brockhoff Chair of Child Public Health, McCaughey VicHealth Centre for
Community Wellbeing, Melbourne School of Population & Global Health,
University of Melbourne), Robert West (Professor of Health Psychology and
Director of Tobacco Studies, Health Behaviour Research Centre, Department of
Epidemiology and Public Health) and Joanne Yaffe (Professor, College of Social
Work, University of Utah).
Funding
This project is funded by the UK Economic and Social Research Council
(ES/K00087X/1).
Availability of data and materials
Methodological protocols, data collection materials, and data from the Delphi
process and consensus meeting can be requested from ReShare, the UK Data
Service’s online data repository (doi: https://doi.org/10.5255/UKDA-SN-851981).
Authors’ contributions
PM, SG and EMW conceived of the idea for the project. PM, SG, EMW, GM,
SM, SH and DM led the project and wrote the first draft of the manuscript.
All authors contributed to and approved the final manuscript.
Ethics approval and consent to participate
Ethics approval was obtained from the Department Research Ethics Committee
for the Department of Social and Intervention, University of Oxford (reference
2011-12_83).
Consent for publication
Not applicable.
Competing interests
SG’s spouse is a salaried-employee of Eli Lilly and Company, and owns stock. SG
has accompanied his spouse on company-sponsored travel. SH and DM are
members of the CONSORT Group. All other authors declare no competing
interest.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.
Author details
1School of Social Policy, University of Birmingham, Edgbaston, Birmingham
B15 2TT, UK. 2Behavioral & Policy Sciences, RAND Corporation, 1776 Main
Street, Santa Monica 90407-2138, CA, USA. 3Department of Epidemiology,
615 North Wolfe Street, E6036, Baltimore 21205, MD, USA. 4School for Policy
Studies, 8 Priory Road, Bristol BS8 1TZ, UK. 5Department of Clinical,
Educational and Health Psychology, Centre for Behaviour Change, London
WC1E 7HB, UK. 6Oxford Clinical Trials Research Unit, Nuffield Department of
Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of
Oxford, Botnar Research Centre, Windmill Road, Oxford OX3 7LD, UK. 7Centre
for Journalology, Clinical Epidemiology Program, Ottawa K1H 8L6, ON,
Canada.
Received: 17 January 2018 Accepted: 8 June 2018
References
1. Petrosino A, Boruch RF, Rounding C, McDonald S, Chalmers I. The Campbell
collaboration Social, Psychological, Educational and Criminological Trials
Register (C2-SPECTR) to facilitate the preparation and maintenance of
systematic reviews of social and educational interventions. Eval Res Educ.
2000;14(3–4):206–19.
2. Bristow D, Carter L, Martin S. Using evidence to improve policy and practice:
the UK what works Centres. Contemp Soc Sci. 2015;10(2):126–37.
3. Social and Behavioral Sciences Team. 2015 Annual Report. Washington, DC:
Executive Office of the President, National Science and Technology Council; 2015.
4. Clark ML, Thapa S. Systematic reviews in the bulletin. Bull World Health
Organ. 2011;89:3.
5. Petrosino A. Reflections on the genesis of the Campbell collaboration. Exp
Criminol. 2013;8(2):9–12.
6. Oliver S, Bagnall AM, Thomas J, et al. Randomised controlled trials for policy
interventions: a review of reviews and meta-regression. Health Technol
Assess. 2010;14(16):1–165.
7. Goodman S, Dickersin K. Metabias: a challenge for comparative
effectiveness research. Ann Intern Med. 2011;155(1):61–2.
8. Moher D, Glasziou P, Chalmers I, et al. Increasing value and reducing waste
in biomedical research: Who's listening? Lancet. 2015; Available online 27
September 2015:doi: 10.1016/S0140-6736(1015)00307-00304
9. Hoffmann TC, Glasziou P, Boutron I, et al. Better reporting of interventions:
template for intervention description and replication (TIDieR) checklist and
guide. BMJ. 2014;348:g1687.
10. Pinnock H, Epiphaniou E, Sheikh A, et al. Developing standards for reporting
implementation studies of complex interventions (StaRI): a systematic
review and e-Delphi. Implement Sci. 2015;10(1):42.
11. Grant S, Mayo-Wilson E, Hopewell S, Macdonald G, Moher D, Montgomery
P. Developing a reporting guideline for social and psychological
intervention trials. J Exp Criminol. 2013;9(3):355–67.
12. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M.
Developing and evaluating complex interventions: the new Medical
Research Council guidance. BMJ. 2008;337:a1655.
13. Michie S, Fixsen D, Grimshaw J, Eccles M. Specifying and reporting complex
behaviour change interventions: the need for a scientific method.
Implement Sci. 2009;4:40.
Montgomery et al. Trials  (2018) 19:407 Page 12 of 14
14. Mayo-Wilson E. Reporting implementation in randomized trials: proposed
additions to the consolidated standards of reporting trials statement. Am J
Public Health. 2007;97(4):630–3.
15. Glasziou P, Meats E, Heneghan C, Shepperd S. What is missing from
descriptions of treatment in trials and reviews? BMJ. 2008;336(7659):1472–4.
16. Nosek BA, Alter G, Banks GC, et al. Promoting an open research culture.
Science. 2015;348:1422–5.
17. Open Science Collaboration. Estimating the reproducibility of psychological
science. Science. 2015;349(6251):aac4716.
18. McNutt M. Reproducibility. Science. 2014;343(6168):229.
19. Open Science Collaboration. An open, large-scale, collaborative effort to
estimate the reproducibility of psychological science. Perspect Psychol Sci.
2012;7(6):657–60.
20. Tajika A, Ogawa Y, Takeshima N, Hayasaka Y, Furukawa TA. Replication and
contradiction of highly cited research papers in psychiatry: 10-year follow-up. Br J
Psychiatry. 2015; Available online July 2015:doi: 10.1192/bjp.bp.1113.143701
21. Michie S, Wood CE, Johnston M, Abraham C, Francis JJ, Hardeman W.
Behaviour change techniques: the development and evaluation of a
taxonomic method for reporting and describing behaviour change
interventions (a suite of five studies involving consensus methods,
randomised controlled trials and analysis of qualitative data). Health Technol
Assess. 2015;19(99):1–187.
22. Glasziou P, Altman DG, Bossuyt P, et al. Reducing waste from incomplete or
unusable reports of biomedical research. Lancet. 2014;383(9913):267–76.
23. Driessen E, Hollon SD, Bockting CLH, Cuijpers P, Turner EH. Does publication
bias inflate the apparent efficacy of psychological treatment for major
depressive disorder? A systematic review and meta-analysis of us national
institutes of health-funded trials. PLoS One. 2015;10(9):e0137864.
24. Ioannidis JP, Munafo MR, Fusar-Poli P, Nosek BA, David SP. Publication and
other reporting biases in cognitive sciences: detection, prevalence, and
prevention. Trends Cogn Sci. 2014;18(5):235–41.
25. Cybulski L, Mayo-Wilson E, Grant S. Improving transparency and
reproducibility: registering clinical trials of psychological interventions
prospectively and completely. J Consult Clin Psychol. 2016;84(9):753–67.
26. Moher D, Schulz KF, Simera I, Altman DG. Guidance for developers of health
research reporting guidelines. PLoS Med. 2010;7(2):e1000217.
27. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I. Improving the
quality of reporting of randomized controlled trials. The CONSORT
statement. JAMA. 1996;276:637–9.
28. Moher D, Schulz KF, Altman D, for the CONSORT Group. The CONSORT
statement: revised recommendations for improving the quality of reports of
parallel-group randomised trials. Lancet. 2001;357(9263):1191–4.
29. Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010
statement: updated guidelines for reporting parallel group randomised
trials. BMJ. 2010;340:698–702.
30. Moher D, Jones A, Lepage L, for the CONSORT Group. Use of the CONSORT
statement and quality of reports of randomized trials: A comparative
before-and-after evaluation. JAMA. 2001;285:1992–5.
31. Turner L, Shamseer L, Altman DG, et al. Consolidated standards of reporting
trials (CONSORT) and the completeness of reporting of randomised
controlled trials (RCTs) published in medical journals. Cochrane Database
Syst Rev. 2012;11:MR000030.
32. Devereaux PJ, Manns BJ, Ghali WA, Quan H, Guyatt GH. The reporting of
methodological factors in randomized controlled trials and the association
with a journal policy to promote adherence to the consolidated standards
of reporting trials (CONSORT) checklist. Control Clin Trials. 2002;23:380–8.
33. Campbell MK, Piaggio G, Elbourne DR, Altman DG. Consort 2010 statement:
extension to cluster randomised trials. BMJ. 2012;345:e5661.
34. Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, for the CONSORT
Group. Reporting of noninferiority and equivalence randomized trials:
extension of the CONSORT 2010 statement. JAMA. 2012;308(24):2594–604.
35. Zwarenstein M, Treweek S, Gagnier JJ, et al. Improving the reporting of
pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390.
36. Vohra S, Shamseer L, Sampson M, et al. CONSORT extension for reporting
N-of-1 trials (CENT) 2015 statement. BMJ. 2015;350:h1738.
37. Eldridge SM, Chan CL, Campbell MJ, et al. CONSORT 2010 statement:
extension to randomised pilot and feasibility trials. BMJ. 2016;355:i5239.
38. Calvert M, Blazeby J, Altman DG, et al. Reporting of patient-reported outcomes
in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814–22.
39. Hopewell S, Clarke M, Moher D, et al. CONSORT for reporting randomised
trials in journal and conference abstracts. Lancet. 2008;371:281–3.
40. Ioannidis JP, Evans SJ, Gotzsche PC, et al. Better reporting of harms in
randomized trials: an extension of the CONSORT statement. Ann Intern
Med. 2004;141:781–8.
41. Boutron I, Moher D, Altman DG, Schulz K, Ravaud P, for the CONSORT
group. Methods and processes of the CONSORT group: example of an
extension for trials assessing nonpharmacologic treatments. Ann Intern
Med. 2008;148(4):W60–6.
42. Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C. Reporting
randomized, controlled trials of herbal interventions: an elaborated
CONSORT statement. Ann Intern Med. 2006;144:364–7.
43. MacPherson H, Altman DG, Hammerschlag R, et al. Revised STandards for
reporting interventions in clinical trials of acupuncture (STRICTA): extending
the CONSORT statement. PLoS Med. 2010;7(6):e1000261.
44. Michie S, Richardson M, Johnston M, et al. The behavior change technique
taxonomy (v1) of 93 hierarchically clustered techniques: building an
international consensus for the reporting of behavior change interventions.
Ann Behav Med. 2013;46:81–95.
45. Michie S, Atkins L, West R. The Behaviour Change Wheel: A guide to
designing interventions. UK: Silverback Publishing; 2014.
46. Michie S, West R, Campbell R, Brown J, Gainforth H. ABC of Behaviour
Change Theories: An essential resource for researchers, policy makers and
practitioners. UK: Silverback Publishing; 2014.
47. Davis RE, Campbell R, Hildon Z, Hobbs L, Michie S. Theories of behaviour
and behaviour change across the social and behavioural sciences: a scoping
review. Health Psychol Rev. 2015;9(3):323–44.
48. Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P. Extending the
CONSORT statement to randomized trials of nonpharmacologic treatment:
explanation and elaboration. Ann Intern Med. 2008;148(4):295–309.
49. Fraser MW, Galinsky MJ, Richman JM, Day SH. Intervention research:
developing social programs. New York: Oxford University Press; 2009.
50. Medical Research Council. Developing and evaluating complex
interventions: New guidance. London: Medical Research Council; 2008.
www.mrc.ac.uk/documents/pdf/complex-interventions-guidance
51. Grant S. Development of a CONSORT Extension for Social and Psychological
Interventions. Oxford: Social Policy & Intervention, University of Oxford; 2014.
52. Institute of Medicine. Psychosocial interventions for mental and substance
use disorders: A framework for establishing evidence-based standards.
Washington, DC: the National Academies Press; 2015.
53. Bonell C, Jamal F, Melendez-Torres GJ, Cummins S. ‘Dark logic’: theorising
the harmful consequences of public health interventions. J Epidemiol
Community Health. 2015;69(1):95–8.
54. May C. Towards a general theory of implementation. Implement Sci. 2013;8:18.
55. Øvretveit J. Evaluating improvement and implementation for health.
Berkshire: Open University Press; 2014.
56. Hawe P, Shiell A, Riley T. Complex interventions: how ‘out of control’ can a
randomised controlled trial be? BMJ. 2004;328(7455):1561–3.
57. Bonell C. The utility of randomized controlled trials of social interventions:
an examination of two trials of HIV prevention. Critical Public Health. 2002;
12(4):321–34.
58. Shadish WR, Cook TD, Campbell DT. Experimental and quasi-experimental
designs for generalized causal inference. Belmont: Wadsworth; 2002.
59. Sniehotta FF, Araújo-Soares V, Brown J, Kelly MP, Michie S, West R. Complex
systems and individual-level approaches to population health: a false
dichotomy? Lancet Public Health. 2017;2(9):e396–7.
60. Weiss MJ, Bloom HS, Brock T. A conceptual framework for studying the
sources of variation in program effects. New York: MDRC; 2013.
61. Montgomery P, Grant S, Hopewell S, et al. Protocol for CONSORT-SPI:
an extension for social and psychological interventions. Implement Sci.
2013;8:99.
62. Grant S, Montgomery P, Hopewell S, Macdonald G, Moher D, Mayo- Wilson
E. Letter to the editor: new guidelines are needed to improve the reporting
of trials in addiction sciences. Addiction. 2013;108:1687–8.
63. Grant S, Montgomery P, Hopewell S, Macdonald G, Moher D, Mayo-Wilson
E. Developing a reporting guideline for social and psychological
intervention trials. Res Soc Work Pract. 2013;23(6):595–602.
64. Mayo-Wilson E, Grant S, Hopewell S, Macdonald G, Moher D, Montgomery
P. Developing a reporting guideline for social and psychological
intervention trials. Trials. 2013;14:242.
65. Mayo-Wilson E, Montgomery P, Hopewell S, Macdonald G, Moher D, Grant
S. Developing a reporting guideline for social and psychological
intervention trials. Br J Psychiatry. 2013;203:250–4.
Montgomery et al. Trials  (2018) 19:407 Page 13 of 14
66. Montgomery P, Grant S, Hopewell S, Macdonald G, Moher D, Mayo-Wilson
E. Developing a reporting guideline for social and psychological
intervention trials. Br J Soc Work. 2013;43(5):1024–38.
67. Montgomery P, Mayo-Wilson E, Hopewell S, G M, Moher D, Grant S.
Developing a reporting guideline for social and psychological intervention
trials. Am J Public Health. 2013;103(10):1741–6.
68. Gardner F, Mayo-Wilson E, Montgomery P, et al. Editorial perspective: the
need for new guidelines to improve the reporting of trials in child and
adolescent mental health. J Child Psychol Psychiatry. 2013;54(7):810–2.
69. Jones J, Hunter D. Consensus methods for medical and health services
research. BMJ. 1995;311(376):376–80.
70. Hopewell S, Altman DG, Moher D, Schulz KF. Endorsement of the CONSORT
statement by high impact factor medical journals: a survey of journal
editors and journal ‘instructions to authors. Trials. 2008;9:20.
71. Moher D, Weeks L, Ocampo M, et al. Describing reporting guidelines for
health research: a systematic review. J Clin Epidemiol. 2011;64(7):718–42.
72. Moher D, Hopewell S, Schultz KF, et al. CONSORT 2010 explanation and
elaboration: updated guidelines for reporting parallel group randomised
trials. BMJ. 2010;340:c869.
73. Murphy MK, Black NA, Lamping DL, et al. Consensus development methods,
and their use in clinical guideline development. Health Technol Assess.
1998;2(3):i-iv, 1–88.
74. Sinha IP, Smyth RL, Williamson PR. Using the Delphi technique to determine
which outcomes to measure in clinical trials: recommendations for the
future based on a systematic review of existing studies. PLoS Med. 2011;
8(1):e1000393.
75. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for
systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration
and explanation. BMJ. 2015;349:g7647.
76. Hopewell S, Ravaud P, Baron G, Boutron I. Effect of editors’ implementation
of CONSORT guidelines on the reporting of abstracts in high impact
medical journals: interrupted time series analysis. BMJ. 2012;344:e4178.
77. Moher D, Altman DG. Four proposals to help improve the medical research
literature. PLoS Med. 2015;12(9):e1001864.
78. Harrison BA, Mayo-Wilson E. Trial registration: understanding and preventing
reporting bias in social work research. Res Soc Work Pract. 2014;24(3):372–6.
79. Chan AW, Tetzlaff JM, Gøtzsche PC, et al. SPIRIT 2013 explanation and
elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.
80. Mayo-Wilson E, Doshi P, Dickersin K. Are manufacturers sharing data as
promised? BMJ. 2015;351:h4169.
81. Miguel E, Camerer C, Casey K, et al. Promoting transparency in social
science research. Science. 2014;343(6166):30–1.
82. Data Access and Research Transparency (DA-RT): a joint statement by
political science journal editors. Pol Sci Res Methods. 2015;3:421. https://
www.dartstatement.org/.
83. Michie S, Thomas J, Johnston M, et al. The human behaviour-change
project: harnessing the power of artificial intelligence and machine learning
for evidence synthesis and interpretation. Implement Sci. 2017;12:121.
84. Tetzlaff JM, Moher D, Chan AW. Developing a guideline for clinical trial
protocol content: Delphi consensus survey. Trials. 2012;13(1):176.
85. Agarwal S, LeFevre AE, Lee J, et al. Guidelines for reporting of health
interventions using mobile phones: mobile health (mHealth) evidence
reporting and assessment (mERA) checklist. BMJ. 2016;352:i1174.
86. Stevens A, Shamseer L, Weinstein E, et al. Relation of completeness of
reporting of health research to journals’ endorsement of reporting
guidelines: systematic review. BMJ. 2014;348:g3804.
87. Des Jarlais DC, Lyles C, Crepaz N, the TREND Group. Improving the reporting
quality of nonrandomized evaluations of behavioral and public health
interventions: the TREND statement. Am J Public Health. 2004;94(3):361–6.
Montgomery et al. Trials  (2018) 19:407 Page 14 of 14
